Literature DB >> 33919322

Acute Responses to Oxygen Delivery via High Flow Nasal Cannula in Patients with Severe Chronic Obstructive Pulmonary Disease-HFNC and Severe COPD.

Amy H Attaway1, Jihane Faress2, Frank Jacono2, Srinivasan Dasarathy3.   

Abstract

Differences in oxygen delivery methods to treat hypoxemia have the potential to worsen CO2 retention in chronic obstructive lung disease (COPD). Oxygen administration using high flow nasal cannula (HFNC) has multiple physiological benefits in treating respiratory failure including reductions in PaCO2 in a flow-dependent manner. We hypothesized that patients with COPD would develop worsening hypercapnia if oxygen fraction was increased without increasing flow rate. We evaluated the acute response to HFNC in subjects with severe COPD when flow remained constant and inspired oxygen was increased. In total, 11 subjects with severe COPD (FEV1 < 50%) on supplemental oxygen with baseline normocapnia (PaCO2 < 45 mm Hg; n = 5) and hypercapnia (PaCO2 ≥ 45 mm Hg; n = 6) were studied. Arterial blood gas responses were studied at three timepoints: Baseline, HFNC at a flow rate of 30 L/min at resting oxygen supplementation for 1 h, and FiO2 30% above baseline with the same flow rate for the next hour. The primary endpoint was the change in PaCO2 from baseline. No significant changes in PaCO2 were noted in response to HFNC applied at baseline FiO2 in the normocapnic and hypercapnic group. At HFNC with FiO2 30% above baseline, the normocapnic group did not show a change in PaCO2 (baseline: 38.9 ± 1.8 mm Hg; HFNC at higher FiO2: 38.8 ± 3.1 mm Hg; p = 0.93), but the hypercapnic group demonstrated significant increase in PaCO2 (baseline: 58.2 ± 9.3 mm Hg; HFNC at higher FiO2: 63.3 ± 10.9 mm Hg; p = 0.025). We observed worsening hypercapnia in severe COPD patients and baseline hypercapnia who received increased oxygen fraction when flow remained constant. These data show the need for careful titration of oxygen therapy in COPD patients, particularly those with baseline hypercapnia when flow rate is unchanged.

Entities:  

Keywords:  COPD; chronic respiratory failure; high flow nasal cannula; hypercapnia; oxygen inhalation therapy; respiratory; structural lung disease; ventilation perfusion mismatch

Year:  2021        PMID: 33919322     DOI: 10.3390/jcm10091814

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  34 in total

1.  High-flow nasal cannula oxygen therapy to treat patients with hypoxemic acute respiratory failure consequent to SARS-CoV-2 infection.

Authors:  Andrea Vianello; Giovanna Arcaro; Beatrice Molena; Cristian Turato; Andi Sukthi; Gabriella Guarnieri; Francesca Lugato; Gianenrico Senna; Paolo Navalesi
Journal:  Thorax       Date:  2020-07-23       Impact factor: 9.139

2.  Domiciliary High-Flow Nasal Cannula Oxygen Therapy for Patients with Stable Hypercapnic Chronic Obstructive Pulmonary Disease. A Multicenter Randomized Crossover Trial.

Authors:  Kazuma Nagata; Takashi Kikuchi; Takeo Horie; Akira Shiraki; Takamasa Kitajima; Toru Kadowaki; Fumiaki Tokioka; Naohiko Chohnabayashi; Akira Watanabe; Susumu Sato; Keisuke Tomii
Journal:  Ann Am Thorac Soc       Date:  2018-04

3.  Comparison of Transcutaneous and Capillary Measurement of PCO2 in Hypercapnic Subjects.

Authors:  Sven Stieglitz; Sandhya Matthes; Christina Priegnitz; Lars Hagmeyer; Winfried Randerath
Journal:  Respir Care       Date:  2015-12-01       Impact factor: 2.258

4.  Effects of nasal high flow on ventilation in volunteers, COPD and idiopathic pulmonary fibrosis patients.

Authors:  Jens Bräunlich; Denise Beyer; David Mai; Stefan Hammerschmidt; Hans-Jürgen Seyfarth; Hubert Wirtz
Journal:  Respiration       Date:  2012-11-01       Impact factor: 3.580

5.  Nasal high flow clears anatomical dead space in upper airway models.

Authors:  Winfried Möller; Gülnaz Celik; Sheng Feng; Peter Bartenstein; Gabriele Meyer; Eickelberg Oliver; Otmar Schmid; Stanislav Tatkov
Journal:  J Appl Physiol (1985)       Date:  2015-06-15

6.  Nasal high flow oxygen therapy in patients with COPD reduces respiratory rate and tissue carbon dioxide while increasing tidal and end-expiratory lung volumes: a randomised crossover trial.

Authors:  John F Fraser; Amy J Spooner; Kimble R Dunster; Chris M Anstey; Amanda Corley
Journal:  Thorax       Date:  2016-03-25       Impact factor: 9.139

7.  Clinical Implications of the New York Heart Association Classification.

Authors:  César Caraballo; Nihar R Desai; Hillary Mulder; Brooke Alhanti; F Perry Wilson; Mona Fiuzat; G Michael Felker; Ileana L Piña; Christopher M O'Connor; Joanne Lindenfeld; James L Januzzi; Lawrence S Cohen; Tariq Ahmad
Journal:  J Am Heart Assoc       Date:  2019-11-27       Impact factor: 5.501

8.  Effectiveness of high-flow nasal cannula oxygen therapy for acute respiratory failure with hypercapnia.

Authors:  Eun Sun Kim; Hongyeul Lee; Se Joong Kim; Jisoo Park; Yeon Joo Lee; Jong Sun Park; Ho Il Yoon; Jae Ho Lee; Choon-Taek Lee; Young-Jae Cho
Journal:  J Thorac Dis       Date:  2018-02       Impact factor: 2.895

9.  Nasal High-flow versus non-invasive ventilation in stable hypercapnic COPD: a preliminary report.

Authors:  Jens Bräunlich; Hans-Jürgen Seyfarth; Hubert Wirtz
Journal:  Multidiscip Respir Med       Date:  2015-09-03

10.  High Flow Nasal Cannula, Is There a Role in COPD?

Authors:  Nicholas S Hill
Journal:  Tanaffos       Date:  2017
View more
  1 in total

1.  Transnasal High-Flow Oxygen Therapy versus Noninvasive Positive Pressure Ventilation in the Treatment of COPD with Type II Respiratory Failure: A Meta-Analysis.

Authors:  Wei Liu; Mingli Zhu; Liuqin Xia; Xiangying Yang; Pei Huang; Yanming Sun; Ye Shen; Jianping Ma
Journal:  Comput Math Methods Med       Date:  2022-07-26       Impact factor: 2.809

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.